High Flow Nasal Cannula Oxygen Therapy (HFNC) With Different Temperatures in COVID-19 Patients: A Randomized Clinical Trial
-
Maryam Sadat Mirenayat
,
Narjes Jalali
,
Somayeh Sadeghi
,
Reyhaneh Zahiri
,
Mitra Lotfalipour
,
Zahra Amraei
,
Atefeh Fakharian
Abstract
Background: The effect of using high flow oxygen delivery through the nasal cannula (HFNC) in COVID-19 patients has been associated with different results. This study aimed to evaluate the effect of different HFNC temperatures in COVID-19 patients.
Methods: Patients were randomly divided into three groups under high current oxygenation with temperatures of 31, 34, and 37. Except for the temperature, other device settings were set equally. After 24 hours, clinical conditions were on the agenda and compared with the conditions before the intervention.
Results: Fever, sore throat, malaise, diarrhea in patients of 31 degree group and indicators of nausea, cough, body pain, headache have changed the most in 37 degree group. Abdominal pain has shown the greatest change in the 34 degree group. PR, DBP, and SpO2 indices changed the most at 31 degrees and RR and SBP at 37 degrees. PR, RR, SBP and SPO2 indices showed significant values in intra-group comparison, and in inter-group comparison, only PR, RR indices had significant differences. In intra-group analysis, PaCO2, WBC, CRP, ESR and ferritin had significant changes, and in inter-group comparison, none of the indicators had significant differences.
Conclusion: Based on the results of the present study, reducing the temperature in the use of HFNC can improve the clinical conditions of patients with COVID-19.
[2] Montenegro F, Unigarro L, Paredes G, Moya T, Romero A, Torres L, et al. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review. Expert Rev Respir Med. 2021; 15(2):183-95.
[3] Frat JP, Ricard JD, Quenot JP, Pichon N, Demoule A, Forel JM, et al. Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial. Lancet Respir Med. 2019; 7(4):303-12.
[4] Koga Y, Kaneda K, Fujii N, Tanaka R, Miyauchi T, Fujita M, et al. Comparison of high‐flow nasal cannula oxygen therapy and non‐invasive ventilation as first‐line therapy in respiratory failure: a multicenter retrospective study. Acute Med Surg. 2019; 7(1):e461.
[5] Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015; 3(1):15.
[6] Yang PL, Yu JQ, Chen HB. High-flow nasal cannula for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Heart & Lung. 2021; 50(2):252-61.
[7] Ignatiuk D, Schaer B, McGinley B. High flow nasal cannula treatment for obstructive sleep apnea in infants and young children. Pediatr Pulmonol. 2020; 55(10):2791-8.
[8] Ko DR, Beom J, Lee HS, You JS, Chung HS, Chung SP. Benefits of high-flow nasal cannula therapy for acute pulmonary edema in patients with heart failure in the emergency department: a prospective multi-center randomized controlled trial. J Clin Med. 2020; 9(6):1937.
[9] Mirenayat M, Abedini A, Kiani A, Eslaminejad A, Adimi Naghan P, Malekmohammad M, et al. National Research Institute of Tuberculosis and Lung Disease (NRITLD) protocol for the treatment of patients with COVID-19. Iran J Pharm Res. 2022; 21(1):e123947.
[10] Mauri T, Galazzi A, Binda F, Masciopinto L, Corcione N, Carlesso E, et al. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Crit Care. 2018; 22(1):1-8.
[11] Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respiratory care. 2010; 55(4):408-13.
[12] Pérez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta. 2008; 1778(7-8):1676-95.
[13] Hunt K. Optimisation of Neonatal Ventilation and Resuscitation (Doctoral dissertation, King's College London).
[14] Raeisi S, Fakharian A, Ghorbani F, Jamaati HR, Mirenayat MS. Value and safety of high flow oxygenation in the treatment of inpatient asthma: a randomized, double-blind, pilot study. Iranian Journal of Allergy, Asthma and Immunology. 2019.
[15] Martonen TB. Deposition patterns of cigarette smoke in human airways. Am Ind Hyg Assoc J. 1992; 53(1):6-18.
[16] Hanna LM, Scherer PW. A theoretical model of localized heat and water vapor transport in the human respiratory tract. J Biomech Eng. 1986; 108(1):19-27.
[17] Haverkamp FJ, Giesbrecht GG, Tan EC. The prehospital management of hypothermia—an up-to-date overview. Injury. 2018; 49(2):149-64.
[18] Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults. Chest. 2015; 148(1):253-61.
[19] Mauri T, Galazzi A, Binda F, Masciopinto L, Corcione N, Carlesso E, Lazzeri M, Spinelli E, Tubiolo D, Volta CA, Adamini I. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Critical Care. 2018; 22(1):1-8.
[20] Chang GY, Cox CA, Shaffer TH. Nasal cannula, CPAP, and high-flow nasal cannula: effect of flow on temperature, humidity, pressure, and resistance. Biomedical Instrumentation & Technology. 2011; 45(1):69-74.
[21] Butt S, Pistidda L, Floris L, Liperi C, Vasques F, Glover G, et al. Initial setting of high-flow nasal oxygen post extubation based on mean inspiratory flow during a spontaneous breathing trial. J Crit Care. 2021; 63:40-4.
| Files | ||
| Issue | Vol 10 No 4 (2024): Autumn |
|
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/aacc.v10i4.16261 | |
| Keywords | ||
| COVID-19 high flow nasal cannula oxygen therapy hypoxia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
